课题基金 / 基金详情

Physiology and Pharmacology of BRS-3 (Bombesin Receptor Subtype-3)

Physiology and Pharmacology of BRS-3 (Bombesin Receptor Subtype-3)
BRS-3(铃蟾肽受体亚型 3)的生理学和药理学
批准号:
8349965
负责人:
MARC L REITMAN
金额:
$91.61万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

MARC L REITMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
I arrived at the NIH during this year and much of my effort has been devoted to setting up my laboratory. We have established a colony of BRS-3 knockout mice. A conditional floxed knockout does not yet exist for BRS-3 and we are in the process of making such a mouse. We also plan to generate a transgenic mouse with Cre recombinase driven by BRS-3. An MTA that enables us to get BRS-3 compounds (MK-5046, MK-7255, and Bantag-1) from Merck has been created. The mouse physiology capabilities needed are also being established, including the ability to measure metabolic rate at thermoneutrality and a telemetry system for continuous body temperature monitoring. Additionally, work on BRS-3 that I was involved with at Merck Research Laboratories prior to my arrival at NIDDK continues to be guided through the publication process.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
REGULATION OF GENE EXPRESSION RELEVANT TO THE ADIPOSE CELL AND OBESITY
Studies in Youths & Young Adults with Obesity & T2DM (07-DK-0115, 10-DK-0163)
Physiology and Pharmacology of BRS-3 (Bombesin Receptor Subtype-3)
What can body temperature tell us about energy homeostasis?
海外基金